DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal

Bulletin Express

03/11

Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and approve the consolidated financial results for the year ended 31 December 2025 and evaluate whether to recommend a final dividend.

The board currently comprises three executive directors—Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Ms. Si Wen—two non-executive directors—Mr. Cai Zhiyang and Dr. Yu Tao—and three independent non-executive directors—Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.

The company will release its audited annual results and any dividend recommendation following board approval. The announcement was released in Hong Kong on 11 March 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1190504580"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190504580\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190504580?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190504580","market":"hk","top_or_hot":-1,"title":"DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal","media":"Bulletin Express","content":"<p>Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and approve the consolidated financial results for the year ended 31 December 2025 and evaluate whether to recommend a final dividend.</p>\n<p>The board currently comprises three executive directors—Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Ms. Si Wen—two non-executive directors—Mr. Cai Zhiyang and Dr. Yu Tao—and three independent non-executive directors—Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.</p>\n<p>The company will release its audited annual results and any dividend recommendation following board approval. The announcement was released in Hong Kong on 11 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-11 16:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and approve the consolidated financial results for the year ended 31 December 2025 and evaluate whether to recommend a final dividend.</p>\n<p>The board currently comprises three executive directors—Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Ms. Si Wen—two non-executive directors—Mr. Cai Zhiyang and Dr. Yu Tao—and three independent non-executive directors—Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.</p>\n<p>The company will release its audited annual results and any dividend recommendation following board approval. The announcement was released in Hong Kong on 11 March 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1190504580","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190504580","pubTimestamp":1773218620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"DUALITYBIO-B(09606)定于2026年3月23日召开董事会批准2025财年业绩并审阅末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and approve the consolidated financial results for the year ended 31 December 2025 and evaluate whether to recommend a final dividend.\nThe board currently comprises three executive directors—Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Ms. Si Wen—two non-executive directors—Mr. Cai Zhiyang and Dr. Yu Tao—and three independent non-executive directors—Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.\nThe company will release its audited annual results and any dividend recommendation following board approval. The announcement was released in Hong Kong on 11 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}